Funding for this research was provided by:
VeloSano Bike to Cure
Laura J. Fogarty Endowed Chair
Received: 6 November 2020
Accepted: 15 March 2021
First Online: 22 April 2021
: OR and PGR are co-directors of the Center for Research Excellence in Gynecologic Cancer at the Cleveland Clinic.
: All mouse experiments were performed with adherence to protocols approved by the Institutional Animal Care and Use Committee at the Lerner Research Institute at the Cleveland Clinic (IACUC protocol #2018 − 1940).
: Not applicable.
: OR has a patent for CD55 as a therapeutic target in cisplatin resistant endometrial cancer pending. CM receives personal fees from Clovis Oncology. The remaining authors have no relevant financial or conflicts of interest to disclose for this work.